Clinical Trials Logo

Filter by:
NCT ID: NCT05001516 Completed - Clinical trials for Advanced Solid Tumor

Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors

Start date: December 29, 2021
Phase: Phase 1
Study type: Interventional

A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of LM-302 in Patients with CLDN18.2-Positive Advanced Solid Tumors

NCT ID: NCT05001399 Completed - Chronic Pain Clinical Trials

Feasibility of Using Holographic Memory Resolution® (HMR) in Patients/Clients With Pain

Start date: October 25, 2021
Phase: N/A
Study type: Interventional

Study Purpose: This study will explore the feasibility of administering Holographic Memory Resolution® (HMR) to adults who are experiencing chronic pain for 6 months or more.

NCT ID: NCT05001347 Completed - Ovarian Cancer Clinical Trials

A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors

Start date: November 2, 2021
Phase: Phase 2
Study type: Interventional

This is a multicenter, open label, Phase 2 study of TJ004309 in combination with atezolizumab in patients with advanced or metastatic solid tumors.

NCT ID: NCT05001165 Completed - Clinical trials for Heart Failure With Reduced Ejection Fraction

Dashboard Activated Services and Tele-Health for Heart Failure

DASH-HF
Start date: September 17, 2021
Phase: N/A
Study type: Interventional

The Dashboard Activated Services and tele-Health for Heart Failure (DASH-HF) study is a pragmatic randomized controlled trial of a quality improvement (QI) intervention of a prospective panel management intervention to optimize medical treatment for Veterans with heart failure with reduced ejection fraction (HFrEF) compared to the receipt of usual VA health care services over a 6-month period of observation. The study will incorporate the existing VA Academic Detailing Heart Failure Dashboard (ADHFD) to target actionable patients with gaps in performance measures for guideline-directed medical therapies (GDMT). Patients with HFrEF are optimally managed by cardiovascular specialty clinics. Typically, patients are referred to cardiology or heart failure (HF) clinics from primary care, emergency department, or post-hospitalization clinicians and scheduled into clinic grids. These patients may be lost to follow-up or clinicians may miss opportunities to optimize GDMT for HFrEF. GDMT includes Class I indicated medications from the following classes: beta blockers (BB), angiotensin-converting enzyme inhibitor (ACE), angiotensin II receptor blockers (ARB), angiotensin receptor neprilysin inhibitor (ARNI), mineralocorticoid receptor antagonist (MRA), sodium-glucose cotransporter-2 inhibitor (SGLT2i). The intervention is designed around a novel prospective panel management clinic led by clinicians or clinical pharmacists using impromptu patient telephone calls or electronic communications with existing responsible clinicians.

NCT ID: NCT05001152 Completed - Healthy Volunteers Clinical Trials

Taste Assessment of Ozanimod

Start date: September 9, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the taste characteristics of ozanimod formulations, alone and mixed, in order to develop a pediatric oral form of ozanimod.

NCT ID: NCT05001126 Completed - Metabolic Syndrome Clinical Trials

The Dose-response Effects of High Intensity Functional Training on Metabolic Syndrome Risk Factors

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

This study aims to explore the dose effects of three weekly volumes of high-intensity functional training (HIFT) on apolipoprotein B (ApoB), triglyceride (TG) and cholesterol (CHOL) content of low-density lipoproteins (LDL), very low-density lipoproteins (VLDL), and high-density lipoproteins (HDL) particles, fasting insulin and glucose, glycosylated hemoglobin (HbA1c), and endothelial function after a 12-week training program. Secondarily, this study aims to also explore the subjective dose-responses of "exercise enjoyment" and "intention to continue" after this 12-week training program.

NCT ID: NCT05000931 Completed - Clinical trials for Conductive Hearing Loss

Osia 2 Pediatric Expansion Study

Start date: January 26, 2022
Phase: N/A
Study type: Interventional

The CochlearTM Osia®2 System was cleared by the Food and Drug Administration November 15, 2019 (K191921) for individuals aged 12 years and older who present with conductive or mixed hearing loss (up to 55 dB HL) or single-sided-deafness (SSD).Published and unpublished data suggest significant pre to postoperative benefit and minimal risk in both children and adults who have received the Osia system. Thus the objective of this study is to examine the safety and effectiveness of the Cochlear Osia 2 system in a group of pediatric subjects aged 5 to 11 years who suffer from conductive or mixed hearing loss (up to 55 dB HL), or single-sided-deafness (SSD) with the intent of expanding the indications for use.

NCT ID: NCT05000879 Completed - Depression Clinical Trials

How Does Mindful Mood Balance for Moms Work?

Start date: November 16, 2018
Phase: N/A
Study type: Interventional

The purpose of this investigation is to conduct a randomized trial comparing a web-based Mindful Mood Balance for Moms course without coaching support to waitlist control among pregnant or early parenting women with depression histories.

NCT ID: NCT05000619 Completed - Prevention Clinical Trials

Encouraging Overdue Healthcare Appointment Scheduling Among Patients With Chronic Diseases

Start date: July 12, 2021
Phase: N/A
Study type: Interventional

The goal of this study is to determine the most effective messages for encouraging patients with chronic conditions, who have not seen their doctor in at least one year, to return to the clinic. Study participants will receive postcards or letters encouraging them to make an appointment. Researchers will assess whether messages increase appointment scheduling (and attendance).

NCT ID: NCT05000502 Completed - Clinical trials for Female Breast Cancer

Exercise, Gut Microbiome, and Breast Cancer: Increasing Reach to Underserved Populations

EMBRACE
Start date: September 1, 2021
Phase: N/A
Study type: Interventional

Understanding the impact exercise has on a cancer survivor's gut microbiome can improve the health and well-being of cancer survivors by enhancing treatments targeting the gut microbiome. Although scientific studies support a link between exercise and the gut microbiome, rigorous randomized trials needed to confirm this causal link are limited and usually involve supervised exercise. Hence, this proposal tests feasibility of a home-based, remote-only research protocol that is more accessible to cancer survivors unable to attend supervised exercise including but not limited to rural populations. This study will also determine if exercise effects on the gut microbiome differ by factors such as race.